TAG:
Jim Davis
Watch Out Pathologists! They’re Coming for Histology!
By R. Lewis Dark | From the Volume XXXI, No. 11 – August 12, 2024 Issue
For any lab that depends on revenue from its histology labo…
Identifying Current Lab Trends from Labcorp & Quest Experience
By Robert Michel | From the Volume XXXI, No. 11 – August 12, 2024 Issue
CEO SUMMARY: Many different factors influence the operations of clinical laboratories in the United States today. One good source of competitive business intelligence is for lab administrators to follow the quarterly earnings calls of the nation’s two biggest public lab corporations. Wi…
Q3 2023 Financial Reports Show Growth at Labcorp, Quest
By Robert Michel | From the Volume XXX, Number 16 – November 13, 2023 Issue
Blood brothers Labcorp and Quest Diagnostics showed momentum beyond COVID-19 testing and toward areas that grew base business revenue in their third quarter (Q3) 2023 financial reporting. Company leaders called attention to more partnerships and acquisitions of ho…
Quest Acquires Lab Outreach from New York-Presbyterian
By Scott Wallask | From the Volume XXX, No. 6 – April 17, 2023 Issue
IT’S THE LATEST DEAL THAT AFFIRMS STATEMENTS by executives of the two largest national labs that hospital CEOs have a growing interest in selling their laboratory outreach businesses. Recently, Quest Diagnostics announced that it will take over the labor…
Labcorp: Ascension Deal Will Earn $550 Million in 2023
By Robert Michel | From the Volume XXX No. 4 – March 6, 2023 Issue
PUBLICLY TRADED LABORATORY COMPANIES OFFERED INSIGHTS into how acquisitions of hospital lab operations and outreach businesses add to their bottom lines, according to recent reports on full-year 2022 and fourth quarter earnings. Last year was a busy one…
Public Laboratory Companies Eye More Lab Outreach Acquisitions
By Robert Michel | From the Volume XXIX, No. 12 – August 29, 2022 Issue
PUBLICLY-TRADED CLINICAL LABORATORY COMPANIES released second quarter 2022 financial reports that confirmed a softening demand for COVID-19 tests, even as their base business revenues grew compared to last year. While continuing to address ongoing needs…
CURRENT ISSUE
Volume XXXI, No. 12 – September 3, 2024
This special intelligence briefing—presented in three parts—identifies the factors retarding a faster adoption of digital pathology. Also, how to protect your lab’s proprietary LDTs and assess the financial impact of compliance.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized